GE (GE) Sale of BioPharma Unit 'Additive' to SOTP - Cowen

February 25, 2019 8:59 AM EST
Get Alerts GE Hot Sheet
Price: $100.47 -0.86%

Rating Summary:
    13 Buy, 13 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Cowen analyst Gautam Khanna weighed in on General Electric (NYSE: GE) after the company agreed to sell BioPharma unit to Danaher for $21.4 billion in cash. He said the valuation is 'additive' to Healthcare's SOTP.

"GE's BioPharma sale to DHR fetched a rich valuation that goes a long way towards GE's debt reduction and therefore, suggests upside to our SOTP math around GE's Healthcare exit," Khanna commented. "The stock should react well to the deal. Moreover, GE posted its event calendar, & now plans its outlook call for 3/14."

The firm maintained a Market Perform rating and price target of $8.00

For an analyst ratings summary and ratings history on General Electric click here. For more ratings news on General Electric click here.

Shares of General Electric closed at $11.85 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Cowen & Co